NDAORALCAPSULE
Approved
Nov 2002
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
15
Data completeness
3/8 — Basic
Drug data last refreshed 14h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
STRATTERA (atomoxetine hydrochloride) is an oral small-molecule selective norepinephrine reuptake inhibitor (NRI) approved for attention-deficit/hyperactivity disorder (ADHD). It is a non-stimulant treatment that increases norepinephrine availability in the brain to improve attention and impulse control.
$0.002BPart D
LOE ApproachingProduct is in mature/declining phase with modest Medicare utilization; brand team likely focused on retention and lifecycle management rather than expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (15)
Impact of Strattera and Behavior Therapy on the Home and School Functioning of Children With ADHD
Started Jan 2007
56 enrolled
Attention Deficit Hyperactivity Disorder
Efficacy and Tolerability of Atomoxetine (Strattera) in Adult Patients With Generalized Social Anxiety Disorder
Started Nov 2005
27 enrolled
Generalized Social Phobia
Assess the Effectiveness of Atomoxetine in Children With Fetal Alcohol Syndrome and ADD/ADHD
Started Aug 2005
38 enrolled
Fetal Alcohol SyndromeAttention Deficit Disorder With Hyperactivity (ADHD)Attention Deficit Disorder (ADD)
Placebo-Controlled Study of Atomoxetine Hydrochloride in the Treatment of Adults With ADHD and Comorbid Social Anxiety Disorder
Started Jun 2005
440 enrolled
Attention Deficit Hyperactivity DisorderComorbid Social Anxiety Disorder
Strattera Treatment in Children With ADHD Who Have Poor Response to Stimulant Therapy
Started Sep 2004
30 enrolled
ADHD
Worked on STRATTERA at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.